KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Free Cash Flow (2017 - 2025)

Alnylam Pharmaceuticals' Free Cash Flow history spans 17 years, with the latest figure at $162.3 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 226.57% year-over-year to $162.3 million; the TTM value through Dec 2025 reached $513.2 million, up 1304.95%, while the annual FY2025 figure was $513.2 million, 1304.95% up from the prior year.
  • Free Cash Flow reached $162.3 million in Q4 2025 per ALNY's latest filing, down from $338.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $342.3 million in Q3 2023 to a low of -$252.8 million in Q1 2021.
  • Average Free Cash Flow over 5 years is -$34.7 million, with a median of -$104.4 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: tumbled 1063.74% in 2024, then skyrocketed 669.44% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$172.0 million in 2021, then skyrocketed by 49.56% to -$86.8 million in 2022, then soared by 115.33% to $13.3 million in 2023, then crashed by 1063.74% to -$128.2 million in 2024, then surged by 226.57% to $162.3 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Free Cash Flow are $162.3 million (Q4 2025), $338.8 million (Q3 2025), and $134.1 million (Q2 2025).